Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Divya SamineniLeonid GibianskyBei WangShweta VadhavkarRicha RajwanshiManeesh TandonArijit SinhaOthman Al-SawafKirsten FischerMichael HallekAhmed Hamed SalemChunze LiDale MilesPublished in: Advances in therapy (2022)
ClinicalTrials.gov Identifiers NCT02242942 and NCT02339181.